Related Experiment Videos

Protection of human polymorphonuclear leukocyte function from the deleterious effects of isolation, irradiation, and

J H Rex1, S C Bhalla, D M Cohen

  • 1Department of Internal Medicine, University of Texas-Houston Medical School, USA.

Transfusion
|July 1, 1995
PubMed
Abstract

Insights

Cytokine treatment, including granulocyte-colony-stimulating factor (G-CSF), preserves polymorphonuclear leukocyte (PMN) function after storage and irradiation. This enhances PMN transfusion efficacy for neutropenic patients with hematologic malignancies.

Area of Science:

  • Hematology
  • Immunology
  • Cell Biology

Background:

  • Fungal infections pose significant challenges for neutropenic patients with hematologic malignancies.
  • Antifungal therapies have limited success, making leukocyte transfusions a problematic alternative.
  • Polymorphonuclear leukocyte (PMN) isolation and irradiation impair function and induce apoptosis.

Purpose of the Study:

  • To evaluate the protective effects of interferon-gamma and G-CSF on PMNs.
  • To assess PMN function after storage and irradiation with cytokine treatment.
  • To determine the optimal cytokine combination for preserving PMN function.

Main Methods:

  • PMNs were stored for 0 or 20 hours and irradiated with 0, 5, or 30 Gy.
  • Interferon-gamma and G-CSF were used alone and in combination.
  • Apoptosis, chemotaxis, Candida albicans killing, and receptor expression were measured.

Main Results:

  • Untreated PMNs showed apoptosis, reduced chemotaxis, and impaired C. albicans killing after 20-hour storage.
  • Cytokine treatment significantly reduced apoptosis and preserved PMN function.
  • G-CSF provided the majority of the protective effect, with combined therapy showing a trend towards better function.

Conclusions:

  • Cytokine administration can preserve PMN function following storage and irradiation.
  • These findings support the judicious use of cytokines to improve PMN transfusion outcomes.
  • Optimized PMN transfusions may benefit cytopenic patients, particularly those with hematologic malignancies.

Related Concept Videos